Breaking
Thursday, July 23, 2026
Share

Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint

Sarah Chen Editor-in-Chief
Reviewed by Sarah Chen Editor-in-Chief
danuglipron drug — Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint
Visual context for this story · not clinical evidence

Decision brief

Answer first · skim in under a minute

Pfizer said danuglipron, its oral GLP-1 receptor agonist, met the primary endpoint in a Phase 2b obesity trial with statistically significant weight loss versus baseline. The result strengthens the case for Danuglipron Phase 3 planning and gives BD and investor teams a fresh benchmark against other oral GLP-1 programs.

Pfizer’s oral GLP-1 candidate danuglipron hit its Phase 2b weight-loss endpoint, but Danuglipron Phase 3 never started for the twice-daily tablet. High dropouts and a later liver-safety review ended the program. Investors should treat the Phase 2b win as a closed chapter, not a late-stage catalyst.

Contents9 sections

Key Takeaways

  • Phase 2b (NCT04707313) met the primary body-weight endpoint versus baseline/placebo adjustment.
  • Placebo-adjusted mean weight loss was about 8%–13% at 32 weeks and 5%–9.5% at 26 weeks.
  • Twice-daily danuglipron will not advance into Phase 3; discontinuation rates exceeded 50%.
  • On April 14, 2025, Pfizer discontinued all danuglipron development after a potential drug-induced liver injury case.

What did the Phase 2b obesity trial show?

Pfizer announced topline Phase 2b results for oral danuglipron (PF-06882961) in adults with obesity without type 2 diabetes. The study met its primary endpoint of statistically significant change in body weight.

Placebo-adjusted mean reductions ranged from roughly 8% to 13% at 32 weeks and 5% to 9.5% at 26 weeks across twice-daily doses. Primary source: Pfizer Phase 2b topline release.

Why did Danuglipron Phase 3 plans stop?

Despite the efficacy signal, Pfizer said high rates of gastrointestinal adverse events and discontinuations meant the twice-daily formulation will not advance into Phase 3 studies. Future work briefly shifted to a once-daily formulation before the full stop in 2025.

  • Nausea up to 73%
  • Vomiting up to 47%
  • Diarrhea up to 25%
  • Discontinuation >50% on drug vs ~40% placebo

What changed in April 2025?

Pfizer later discontinued development of danuglipron entirely. Dose-optimization studies of once-daily formulations (NCT06567327 and NCT06568731) met pharmacokinetic objectives, but a single asymptomatic participant had potential drug-induced liver injury that resolved after stopping the drug.

After reviewing the full clinical package and regulator input, Pfizer ended the molecule. See Business Wire: danuglipron update (April 14, 2025) and the matching Pfizer update.

How BD teams should read the catalyst now

The Phase 2b hit is real but incomplete as a franchise story. Oral GLP-1 competition moved on while Pfizer redirected obesity R&D. Claims that danuglipron is “heading to Phase 3” are outdated against the company’s own December 2023 and April 2025 notices.

Related context: Pfizer company profile and obesity coverage.

What remains unproven

No Phase 3 efficacy or safety package exists for danuglipron. Placebo-adjusted Phase 2b weight loss should not be extrapolated to approved oral GLP-1 products. Liver-enzyme rates were described as class-like overall, but the single DILI-like event still closed the program.

Related NovaPharma coverage

Frequently Asked Questions

Did danuglipron meet its Phase 2b obesity endpoint?

Yes. Pfizer’s Phase 2b trial (NCT04707313) of twice-daily oral danuglipron in adults with obesity without type 2 diabetes showed placebo-adjusted mean weight reductions of about 8% to 13% at 32 weeks and 5% to 9.5% at 26 weeks.

Will Danuglipron Phase 3 studies proceed?

No. In December 2023 Pfizer said the twice-daily formulation will not advance into Phase 3. On April 14, 2025, Pfizer discontinued all danuglipron development after a potential drug-induced liver injury case and regulator input.

What tolerability issues appeared in Phase 2b?

Gastrointestinal adverse events were common: nausea up to 73%, vomiting up to 47%, and diarrhea up to 25%. Discontinuation exceeded 50% across danuglipron doses versus about 40% on placebo.

Primary Sources

  1. Pfizer: Phase 2b danuglipron topline results
  2. Business Wire: Pfizer discontinues danuglipron (April 2025)
  3. ClinicalTrials.gov: NCT04707313

Regulatory catalyst tracker

Track PDUFA dates, approval milestones, and label updates for danuglipron.

  • Jul 12, 2026 — PDUFA target
  • Priority Review — designation
  • Oncology — therapeutic area
Unlock full calendar →

Pfizer pipeline snapshot

One-screen view of active programs, phases, and recent catalysts from public sources.

View public profile →

Entity graph

Continue Exploring

Open the drugs, companies, and topics behind this story.

This article follows our editorial standards. Report a correction via editorial contact.

Deeper reading

Industry reports & whitepapers

Browse all whitepapers →